Twist Bioscience Corporation Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Twist Bioscience Corporation (TWST) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $0 for the 3-month period ending 2023-12-31, per its 10-Q filed 2024-02-02.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2024-11-18
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-12-31 was $0.00.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-09-30 was -$3.33M.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-06-30 was $0.00.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-03-31 was $0.00.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$5.43M.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$6.40M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-Q · filed 2024-02-02 | -$3.33M derived: sum of 2 quarters · filed 2024-11-18 | -$3.33M derived: sum of 3 quarters · filed 2024-11-18 | -$3.33M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2023-09-30 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | -$3.33M derived: sum of 2 quarters · filed 2024-11-18 | -$3.33M derived: sum of 3 quarters · filed 2024-11-18 | -$5.43M 10-K · filed 2024-11-18 | $2.10M 10-K · filed 2023-11-21 | |
| 2023-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $0.00 derived: sum of 2 quarters · filed 2023-08-07 | -$2.10M 10-Q · filed 2023-08-07 | -$3.30M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2023-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | -$2.10M 10-Q · filed 2023-05-08 | -$3.30M derived: sum of 3 quarters · filed 2023-06-05 | -$5.70M derived: sum of 4 quarters · filed 2023-06-05 | ||
| 2022-12-31 | -$2.10M 10-K · filed 2024-11-18 | -$2.10M 10-Q · filed 2023-02-07 | -$3.30M derived: sum of 2 quarters · filed 2023-06-05 | -$5.70M derived: sum of 3 quarters · filed 2023-06-05 | -$7.80M derived: sum of 4 quarters · filed 2023-06-05 | |
| 2022-09-30 | -$1.20M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | -$3.60M derived: sum of 2 quarters · filed 2023-06-05 | -$5.70M derived: sum of 3 quarters · filed 2023-06-05 | -$6.40M 10-K/A · filed 2023-06-05 | ||
| 2022-06-30 | -$2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | -$4.50M derived: sum of 2 quarters · filed 2022-08-08 | -$5.20M 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | -$2.80M 10-Q · filed 2022-05-06 | ||||
| 2021-12-31 | -$700.00K 10-Q · filed 2022-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |